Key facts
- aiwell’s last known valuation is $11.9M (Jul 2021).
- It has raised $1.9M; the latest was Angel (individual) in Jan 2025.
- Notable investors include Japan External Trade Organization, Taisho Pharmaceutical Holdings, Burrows Financial Holdings, Contrail, Digimars — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for aiwell
- ·The full record, as it builds
Funding rounds
No funding rounds for aiwell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About aiwell
Developer of artificial intelligence-based proteomics designed for the analysis of the body. The company's proteomics uses two-dimensional electrophoresis technology for handling a large number of samples and increasing the sensitivity to analyze a small number of samples, enabling medical practitioners to arrive at accurate judgments about sepsis.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2018
- Website
- aiwelljapan.com/
- Ownership
- Privately Held (backing)
aiwell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in aiwell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on aiwell in its N-PORT filings yet. We sweep new filings monthly.